AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 172 min read$ADIL

ADIAL PHARMACEUTICALS, INC. (ADIL): Results of Operations and Financial Condition

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative

Original reporting
SEC EDGAR 8-K
Published Aug 17, 2026, 11:17 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 11:37 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$ADIL
Neutral
low confidence
Mentioned
$ADIL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ADILNeutralLow
01

Why it matters

Traders should treat this as a scheduled disclosure event, but the provided text does not reveal the magnitude of any earnings surprise, balance-sheet changes, or guidance updates that would drive price action.

02

Market read

This filing signals quarterly financial reporting was released, but the scrape does not include the results needed to assess whether it is a catalyst.

03

What to watch

The scrape omits the actual financial statements and any forward-looking statements in Exhibit 99.1, which are the key drivers for trading decisions.

Relevance 7/10Novelty 2/10Timing: filed Aug 17, 2026 pre-market/early session via 8-K

Background

The company submitted SEC Form 8-K under Item 2.02 to report results of operations and financial condition, referencing a press release for the quarter ended June 30, 2026.

Company-level read

Ticker impact

$ADILNeutralLow confidence
Context

Adial Pharmaceuticals filed an 8-K with Item 2.02, attaching its press release with financial information for the quarter ended June 30, 2026.

Expected impact

Near-term price impact is likely limited unless the attached Exhibit 99.1 contains material beats, misses, or guidance changes not shown in the scrape.

Evidence & confidence

The filing confirms the quarter ended June 30, 2026 results were issued, but the article body provides no numbers, outlook, or operational updates from Exhibit 99.1.

Market effects

Sector

No sector-level implications are disclosed in the provided text beyond a standard biotech quarterly reporting event.

Regional

No regional market effects are described.

Global

No global relevance is described.

Counterpoint

What could challenge this read

If Exhibit 99.1 includes a surprise loss, cash burn change, or updated runway, the market reaction could be larger than a typical 8-K results filing suggests.

Key entities

  • issuer
    Adial Pharmaceuticals, Inc.

    Nasdaq-listed company filing an 8-K with quarterly financial information for the quarter ended June 30, 2026.

  • executive
    Cary J. Claiborne

    President and Chief Executive Officer signing the 8-K.

Read at source← All news

Related articles

JUN 12
$ADILMedAI 9/10

Adial Acquires Azora With $64 Mln Private Placement; To Advance AT177 For Ulcerative Colitis

Adial Pharmaceuticals said it will acquire Azora Therapeutics and obtain its lead asset AT177 for ulcerative colitis. The deal is paired with a $64 million private placement, including $32 million upfront, issuing pre-funded warrants for 11,780,948 shares at $2.7489. A further $32 million milestone is tied to Phase 1 start. Proceeds will fund AT177 development; proof-of-concept studies are planned for 2027.

rttnews.com4 min
JUN 11
$ADILMed

ADIAL PHARMACEUTICALS, INC. (ADIL): Completion of Acquisition or Disposition of Assets

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029444801ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JUNE 11, BY AND AMONG ADIAL PHARMACEUTICALS, INC., ADIAL FIRST MERGER SUB, INC., ADIAL SECOND MERGER SUB, LLC AND AZORA THERAPEUTICS, INC Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among: Adi

SEC EDGAR 8-K6 min
SEP 7
$OLLIHighAI 8/10

Ollie's Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

Ollie's Bargain Outlet (NASDAQ: OLLI) shares fell after Q2 earnings, despite adjusted EPS of $1.42 beating expectations. Weak comparable-store sales were offset by margin gains and store growth. The company is converting former Big Lots stores, driving a 12% store count increase. Analysts maintain a 'Moderate Buy' rating with 40% upside potential, citing margin recovery and share buybacks.

yahoo.com3 min
SEP 7
$UWMCHighAI 9/10

Why UWM Holdings Stock Dived by 20% Last Month

United Wholesale Mortgage (UWMC) reported Q2 revenue of $888M, up 17% YoY, but a net loss of $367M due to a $603M loss on interest rate derivatives. The company suspended its dividend and announced a $2B capital-raising effort, including a $1.65B equity sale and a $400M rights offering. UWMC's stock fell over 20% in August.

yahoo.com3 min
SEP 7
$CANGMed

Cango (CANG) Q2 2026 Earnings Call Transcript

Cango Inc. (CANG) reported Q2 2026 revenue of $50.8M, down 50% QoQ, with a net loss of $81.6M due to impairment and disposal losses. Bitcoin production fell to 656 BTC. The company reduced its hashrate, transitioning to a leasing model and starting a hedging program. It also completed its first AI infrastructure site, expecting AI revenue to begin in Q3 2026. Cash and equivalents were $10.1M, with long-term debt at $31.2M.

aol.com2 min